NEW YORK — Chinese biotech firm SeekIn said on Thursday that it has received CE marking for its SeekInCare Cancer Detection Kit, a DNA-based blood test for early cancer detection.
SeekInCare uses artificial intelligence to analyze genomic and epigenetic alterations, along with protein biomarkers, to identify cancers and their tissues of origin in blood samples. It was launched as a laboratory-developed test in China in 2018 and, with the CE mark, is set for commercialization in Europe.
"Combining [genomic and epigenetic features] with the conventional protein markers, this test will be able to detect dozens of cancer types in asymptomatic patients when cancer is more likely to be curable," SeekIn founder and CEO Mao Mao said in a statement. "We will continue our efforts to meet additional regulatory requirements in Europe, and to obtain regulatory approvals in the other territories such as China and Japan."
In addition to its pan-cancer test, SeekIn has also explored tests for specific cancers including liver cancer.